Evogene Q4 EPS $(0.13) Beats $(0.14) Estimate, Sales $578.00K Beat $500.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Evogene (NASDAQ:EVGN) reported Q4 earnings with losses of $(0.13) per share, surpassing the consensus estimate of $(0.14) by 7.14%. Year-over-year, this represents an 85.71% increase in losses from $(0.07) per share. Quarterly sales reached $578.00K, beating the $500.00K estimate.
March 07, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evogene reported a smaller-than-expected Q4 loss and higher sales, indicating potential operational improvements.
Beating both earnings and sales estimates typically generates positive investor sentiment, potentially leading to a short-term stock price increase. The improvement over analyst expectations suggests operational efficiency or growth that investors may view favorably.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100